Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine
Authors:
- R WistarRWR Wistar
- S.L HoffmanSHS.L Hoffman
- D.M GordonDGD.M Gordon
- U KrzychUKU Krzych
- J.E EganJEJ.E Egan
- J.D ChulayJCJ.D Chulay
- M GrossMGM Gross
- M.R HollingdaleMHM.R Hollingdale
- 1 April 1991
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 337 (8748) , 998-1001
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Development of sporozoite vaccines for malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1989
- PHASE I CLINICAL TRIAL OF A WORLD HEALTH ORGANISATION BIRTH CONTROL VACCINEThe Lancet, 1988
- SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINEThe Lancet, 1987
- INFLUENZA VACCINATION WITH ADJUVANT RU41740 IN THE ELDERLYThe Lancet, 1987
- Clinical Evaluation of the Immunoadjuvant Murabutide, a Derivative of MDP, Administered with a Tetanus Toxoid VaccineThe Journal of Infectious Diseases, 1986
- Antibody avidity determination by ELISA using thiocyanate elutionJournal of Immunological Methods, 1986
- Enhancement of antibody response to a natural fragment of streptococcal M protein by murabutide administered to healthy volunteersInternational Journal of Immunopharmacology, 1985
- Phase-I study of intravenous modified lipid ACancer Immunology, Immunotherapy, 1984
- Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strainsNucleic Acids Research, 1980
- Vaccine AdjuvantsClinical Infectious Diseases, 1980